207 results about "Metal Chelator" patented technology

Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.

The present invention provides methods and compositions comprising at least one neutral metalloprotease enzyme that has improved stability in the presence of a metal chelator. In some embodiments, the neutral metalloprotease finds use in cleaning and other applications comprising citrate. In some particularly preferred embodiments, the present invention provides methods and compositions comprising variant neutral metalloprotease(s) engineered to resist citrate-induced autolysis.

Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder. In another embodiment, the composition is in the form of a film, wafer, lozenge, capsule, or tablet. In a third embodiment, a dry powdered insulin is mixed with a diluent containing a pharmaceutically acceptable carrier, such as water or saline, a metal chelator such as EDTA and an acid such as citric acid. Devices for storing and mixing these formulations are also described.

A method of treatment of a contaminated material contaminated with an organic compound. The method includes treating the contaminate with a bioremediation step followed by a chemical oxidation step. The bioremediation step includes contacting the contaminate with a microbial consortium under conditions suitable for the consortium to mediate solubilization or biodegradation of the organic compound or chemical oxidation products thereof. The subsequent chemical oxidation step includes treating the bioremediated contaminate with: a transition metal in soluble form; a chelator of the transition metal, to form a transition metal:chelator complex; an oxidizing agent that provides a reactive free radical in the presence of the transition metal complex; and a buffering compound to maintain the pH in a neutral range. The reactive free radical initiates a chemical reaction with the organic compound to produce reaction products of the organic compound.

New and improved compounds for use in diagnostic imaging or therapy having the formula M—N—O—P—G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and / or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

The present invention relates to kinase sensors comprising a metal chelator and a fluorophore, where the chelator comprises a quinoline group and where the fluorophore is conjugated to the chelator. The invention also relates to methods of using these kinase sensors as well as kits comprising the kinase sensors.

Nanometer-scaled up-converting fluoride phosphor particles and processes of making them are disclosed. In the process, an aqueous solution consisting of soluble salts of rare-earth metal ions at a molar ratio of (yttrium, lanthanum or gadolinium): ytterbium:(erbium, holmium, terbium or thulium)=(70-90):(0-29):(0.001-15) is mixed a rare-earth metal chelator and a soluble fluoride salt to form precipitates, which are then annealed at an elevated temperature to produce nanometer-scaled up-converting fluoride phosphor particles. The particle size is between 35 nm and 200 nm, and can be controlled by the amount of the metal chelator added to the solution. The nanometer-sized particle is applicable to many biological assays.